Browsing Anatomy and Neuroscience - Journal Articles by Subject "6-hydroxydopamine"
Now showing 1 - 2 of 2
Results Per Page
- ItemExpression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease.(Springer, 2014-05) Collins, Louise M.; Gavin, Aisling M.; Walsh, Sinéad; Sullivan, Aideen M.; Wyatt, Sean L.; O'Keeffe, Gerard W.; Nolan, Yvonne M.; Toulouse, André; Health Research Board; Science Foundation Ireland; College of Medicine and Health, University College CorkWe have previously demonstrated that mitogen-activated protein kinase phosphatase 1, Mkp1, is expressed in the developing and rat adult substantia nigra and striatum, where it promotes the growth of nigral dopaminergic neurons. Mkp1 may therefore have therapeutic potential for Parkinson's disease. In the present study, we have assessed the expression of Mkp1 and TH in the substantia nigra and striatum of parkinsonian rat models. Expression was measured at 4 and 10 days post-lesion in the 6-hydroxydopamine (6-OHDA) medial forebrain bundle lesion model and after 4, 10 and 28 days in the 6-OHDA striatal lesion model. Our results show that Mkp1 expression was transiently up-regulated in the substantia nigra at 4 days post-6-OHDA administration in the two models while TH expression was decreased at the later time-points examined. These data suggest that Mkp1 may play a role in counteracting the neurotoxic effects of 6-OHDA in nigral dopaminergic neurons.
- ItemNeurotrophic effects of growth/differentiation factor 5 in a neuronal cell line(Springer-Verlag, 2012) Toulouse, André; Collins, Grace C.; Sullivan, Aideen M.; Higher Education AuthorityThe neurotrophin growth/differentiation factor 5 (GDF5) is studied as a potential therapeutic agent for Parkinson's disease as it is believed to play a role in the development and maintenance of the nigrostriatal system. Progress in understanding the effects of GDF5 on dopaminergic neurones has been hindered by the use of mixed cell populations derived from primary cultures or in vivo experiments, making it difficult to differentiate between direct and indirect effects of GDF5 treatment on neurones. In an attempt to establish an useful model to study the direct neuronal influence of GDF5, we have characterised the effects of GDF5 on a human neuronal cell line, SH-SY5Y. Our results show that GDF5 has the capability to promote neuronal but not dopaminergic differentiation. We also show that it promotes neuronal survival in vitro following a 6-hydroxydopamine insult. Our results show that application of GDF5 to SH-SY5Y cultures induces the SMAD pathway which could potentially be implicated in the intracellular transmission of GDF5 s neurotrophic effects. Overall, our study shows that the SH-SY5Y neuroblastoma cell line provides an excellent neuronal model to study the neurotrophic effects of GDF5.